Immunology-oncology ELISA Kits Market
Number of pages: 100 | Report Format: PDF | Published date: May 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 19.63 billion |
|
Revenue Forecast in 2031 |
US$ 27.74 billion |
|
CAGR |
3.9% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Test Type, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global immunology-oncology ELISA kits market was valued at US$ 19.63 billion in 2022 and is expected to register a revenue CAGR of 3.9% to reach US$ 27.74 billion by 2031.
Immunology-oncology ELISA Kits Market Fundamentals
Immunology-oncology ELISA kits are diagnostic tools used to measure various biomarkers and cytokines levels in the blood or other bodily fluids. These biomarkers and cytokines can provide insights into the immune response to cancer and help identify new therapeutic targets. ELISA stands for enzyme-linked immunosorbent assay. An ELISA test adds a sample (usually blood or serum) to a microplate coated with a specific antigen or antibody. If the antigen or antibody is present in the sample, it will bind to the corresponding antibody or antigen on the plate. The plate is then washed to remove any unbound material, and an enzyme-linked secondary antibody is added to the plate. This secondary antibody will bind to the primary antibody or antigen, and any excess is washed away. Finally, a substrate solution is added to the plate, which produces a signal that can be detected and quantified using a spectrophotometer or other detection system.
Immunology-oncology ELISA kits can be used to measure a variety of biomarkers and cytokines, including tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin 2 (IL-2), interleukin 6 (IL-6), and others. These kits can be used in research and clinical settings to monitor the immune response to cancer and evaluate cancer treatments’ efficacy.
The global immunology-oncology ELISA kits industry analysis report comprehensively analyzes the market, with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the Immunology-oncology ELISA kits market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the Immunology-oncology ELISA kits market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
[85685]
Immunology-oncology ELISA Kits Market Dynamics
The rising prevalence of cancer is one of the primary drivers of the growth of the global immunology-oncology ELISA kits market. For instance, according to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, accounting for an estimated 10 million deaths in 2020. As a result, the growing demand for more accurate and efficient cancer diagnostics and treatments drives the demand for immunology-oncology ELISA kits. Moreover, the development of new and advanced technologies, such as high-throughput ELISA platforms, has improved the accuracy and efficiency of cancer diagnostics. These developments have produced ELISA kits that are more sensitive and focused, which are increasingly used in the detection and treatment of cancer and are also helping in the growth of the global immunology-oncology ELISA kits market.
Additionally, high costs, limited availability of trained personnel, and limited availability of trained personnel are some of the restraints impeding the overall immunology-oncology ELISA kits market growth.
Immunology-oncology ELISA Kits Market Ecosystem
Immunology-oncology ELISA Kits Market, by Test Type
Immunology-oncology ELISA Kits Market, by End User
Immunology-oncology ELISA Kits Market by Test Type
[786755]
The direct ELISA test market is expected to grow with a CAGR of 4.1% during the forecast period. Direct ELISA is an enzyme-linked immunosorbent assay (ELISA) commonly used in the immunology-oncology ELISA kits market to measure the levels of specific antigens in a sample. This type of ELISA relies on directly binding an antibody to an antigen without needing a secondary antibody. A microplate is coated with an antigen of interest in a direct ELISA. The plate is then filled with a sample (typically blood, serum, or tissue) and allowed to incubate. If the antigen of interest is present in the sample, it will bind to the associated antibody in the plate. The plate is then rinsed to eliminate unattached material before adding an enzyme-linked secondary antibody. This secondary antibody will bind to the primary antibody linked to the antigen, washing away any excess. Finally, a substrate solution is applied to the plate, resulting in a signal that may be detected and measured using a spectrophotometer or other detection instrument.
The market segmentation sections provide the immunology-oncology ELISA kits market outlook in terms of the demarcation of different consumer groups. Market segmentation is the split of an industry into subgroups depending on characteristics such as test type and end user. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential immunology-oncology ELISA kits market demand opportunities.
Immunology-oncology ELISA Kits Market by Region
North America dominated the market with the largest market share, being the home to many biotechnology and pharmaceutical companies, the rising prevalence of cancer, and academic and research institutions, are driving the demand for these kits. For instance, according to the HIV.gov statistics of October 2022, approximately 1.2 million people in the U.S. have HIV, and 13% of these individuals didn’t even know it. Moreover, the high incidence of COVID-19 screening tests and the growing use of immunoassay testing at POC facilities and central labs are some of the major drivers of the market growth.
The Asia Pacific region is expected to have the fastest growth rate between 4.2 - 4.4% during the forecast period, owing to rising research & development activities and the increasing geriatric population.
Based on the regions, the global immunology-oncology ELISA kits market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of Immunology-oncology ELISA kits industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level immunology-oncology ELISA kits market overview.
Key Components of the Report
Immunology-oncology ELISA Kits Market Competitive Landscape
The market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Immunology-oncology ELISA Kits Market Strategic Developments
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Immunology-oncology ELISA kits are diagnostic tools used to measure various biomarkers and cytokines levels in the blood or other bodily fluids.
The global immunology-oncology ELISA kits market was valued at US$ 19.63 billion in 2022.
North American region will have the largest immunology-oncology ELISA kits market size during the forecast period from 2023 to 2031.
The revenue CAGR of the immunology-oncology ELISA kits market during the forecast period will be 3.9% from 2023 to 2031.
Growing research activities is the most prominent immunology-oncology ELISA kits industry trend.
The limited availability of trained personnel and the high cost of treatment are key challenges hampering the growth of the global immunology-oncology ELISA kits market.
Technological advancements and increasing incidence of cancer are growth opportunities in the global immunology-oncology ELISA kits market.
Some of the prominent players in the immunology-oncology ELISA kits market are Thermo Fisher Scientific Inc., Creative Diagnostics, Bio-Rad Laboratories Inc., Sigma-Aldrich, F. Hoffmann-La Roche Ltd., Danaher Corporation, PerkinElmer Inc, Merck KGaA, Abcam Plc, Agilent Technologies, and Aviva Systems Biology Corporation.
The test type segment has the highest share in the global immunology-oncology ELISA kits market.
*Insights on financial performance are subject to the availability of information in the public domain